Time to initial clinician-reported inactivation of neovascular age-related macular degeneration treated primarily with ranibizumab

Fight Retinal Blindness Study Group

Research output: Contribution to journalArticlepeer-review

22 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Time to initial clinician-reported inactivation of neovascular age-related macular degeneration treated primarily with ranibizumab'. Together they form a unique fingerprint.

Medicine & Life Sciences